Last reviewed · How we verify
Moditen Enanthate (FLUPHENAZINE ENANTHATE)
Moditen Enanthate, also known as Fluphenazine Enanthate, is a phenothiazine antipsychotic medication originally developed by Apothecor and currently owned by the same company. It targets the D3 dopamine receptor to treat psychotic disorders and schizophrenia. This medication is classified as a small molecule and was FDA-approved in 1967. As it is off-patent, there are no active generic manufacturers. Key safety considerations include the potential for extrapyramidal symptoms and tardive dyskinesia.
At a glance
| Generic name | FLUPHENAZINE ENANTHATE |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Phenothiazine |
| Target | D(3) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1967 |
Approved indications
- Psychotic disorder
- Schizophrenia
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moditen Enanthate CI brief — competitive landscape report
- Moditen Enanthate updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI